Conneqt Health Limited has released a press release.
Positive Novartis drug trial using SphygmoCor XCEL
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Conneqt Health
- AtCor completes share placement
- Leading research team highlights role of SphygmoCor
- FY2016 results
- Large national plan to reimburse SphygmoCor test
- $0.6 million pharmaceutical trial extension
Later from Conneqt Health
- Tax refund
- Study Finds Central Aortic Waveform Improves HF Treatment
- AtCor Signs Local Health System Agreement
- Business update and Strategic Review
- AtCor Signs New Network Health Systems Agreement
Follow Conneqt Health into a list and get an email when it puts out news.
Follow Conneqt Health